Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564194 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
A Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV), sponsored by Immorna Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT06564194 is a Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV) that is active but no longer recruiting, run by Immorna Biotherapeutics. The registered enrollment target is 75 participants, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06564194, a Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV), is active but no longer recruiting, sponsored by Immorna Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL JCXH-108
Study Locations (3)
Florida
- Health Awareness - Jupiter
Louisiana
- DelRicht - New Orleans - New Orleans
Missouri
- Sundance Clinical Research - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06564194
The ClinicalTrials.gov registry entry for NCT06564194 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The listed sponsor is Immorna Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Infectious Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06564194 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Louisiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT06564194 about?
NCT06564194 is a clinical study titled "A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV". The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
What is the current status of trial NCT06564194?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2024-09-25. Estimated completion is 2025-06.
What conditions does trial NCT06564194 study?
This clinical trial studies the following conditions: Infectious Disease, Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT06564194?
The interventions under investigation include: Placebo (OTHER), JCXH-108 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06564194?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564194 being conducted?
This trial has 3 study locations across Florida, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infectious Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
COMPLETED · Phase 1
-
Compliant Analysis of Patient Samples and Data
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
Triage Survey for Infectious Disease Eligibility
RECRUITING
-
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.